
|Videos|February 25, 2014
Idelalisib in CLL and iNHL
Author(s)Anas Younes, MD
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses treatment with idelalisib for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL)
Advertisement
Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses treatment with idelalisib for chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL).
Clinical Pearls:
- Idelalisib is a PI3K-delta-specific inhibitor
- Idelalisib demonstrated promising results in various trials in CLL and iNHL
- Idelalisib has little side effects, is very well tolerated, and improves quality of life
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Varegacestat Achieves PFS Gains, Deep Shrinkage of Desmoid Tumors
3
Deep Proteomic, AI Breast Cancer Detection Test Demonstrates High Performance
4
Erdafitinib Demonstrates Manageable Toxicity, Early Efficacy in Glioma
5









































